Drug Trial Radar · NCT03940404
Anlotinib Therapy in Patients With Advanced Lung Cancer.
Last checked: Nov 20, 2026Latest source record: May 7, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
May 2019
Primary completion
May 2020
Study completion Dec 2020
Sponsor
- Lead sponsor
- First People's Hospital of HangzhouAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cttq
- First posted
- May 7, 2019
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Purpose of the study: To observe the efficacy and safety of Anlotinib Hydrochloric Therapy in Patients with advanced Lung cancer in real world. Subjects of the study: advanced Lung cancer. Methods of the study: This is a real world, prospective, Non-Interventional, Follow-up registration study. Patients will get Anlotinib according to their condition and willingness. Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. After the procedure, regular follow up after every cycle. End point: Primary end point: progression-free survival (PFS). Secondary end points: overall survival (OS), disease control rate (DCR), overall response rate (ORR).
Conditions
- Lung Neoplasms
Interventions
Anlotinib HydrochlorideDrug
Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFSTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First People's Hospital of Hangzhou
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.